ISCL is a Intelligent Information Consulting System. Based on our knowledgebase, using AI tools such as CHATGPT, Customers could customize the information according to their needs, So as to achieve

New Changes To Guidelines For Anemia Will Impact EPO Treatment In Chronic Kidney Disease Patients

1
Published December 3rd, 2013 in the Annals of Internal Medicine, the American College of Physicians (ACP), recommended against using Erythropoiesis-Stimulating Agents (ESAs), commonly referred to as "EPO," in patients with mild to moderate anemia and Congestive Heart Failure or Coronary Artery Disease. The harms outweigh the benefits because they cause an increased risks of thromboembolic (blood vessel clotting) events and stroke rates. This should be taken as major news for those with Chronic Kidney Disease (CKD) since both Cardiovascular Disease and Anemia are common challenges in the CKD Community.

Recommended Reading: Why EPO Can Be Harmful to Individuals Suffering with Chronic Kidney Disease

According to Davita Health Care Partners, Cardiovascular Disease is common in people with CKD "regardless of age, stage of kidney disease or if they've had a transplant." Additionally, several studies have revealed that anemia can be related to Cardiovascular Disease such as Coronary Artery Disease because the lack of kidney function prevents Erythropoietin from creating red blood cells. Fewer red blood cells mean less oxygen goes to the body's tissues and organs such as the heart which can induce a heart attack. Anemia, present in approximately 10% to 20% percent of individuals with Coronary Artery Disease, can substantially worsen CKD patients' outcomes, increase risk of hospitalization, decrease exercise capacity, and lead to a poor quality of life generally.


Recommended Reading: Increased Transfusion among CKD Individuals, Troubling Trend

As an alternative solution to anemia, aside from ESAs (Aranesp, Epogen, and Procrit), the ACP's new guidelines reveal that "Transfusion may benefit patients with lower hemoglobin levels, less than 7 - 8 g/dL, but the evidence suggests that red blood cell transfusion for milder anemia in patients with heart disease does not improve mortality," said Dr. Molly Cooke, President of the ACP. Further, emerging evidence shows a short term benefit of intravenous (IV) iron in patients, but ACP found evidence lacking on long-term outcomes.

Recommended Reading: Current Anemia Management Practices May Put Chronic Kidney Disease Patients At Severe Health Risk

Researchers further suggest that limiting ESAs and creating "More modest hemoglobin targets" may improve the quality of life for patients with mild to moderate anemia and heart disease including those with CKD.
PURCHASE YOUR $5.00 "NO BLOOD PRESSURE (BP)/NO NEEDLE STICK (STICK)"
MEDICAL ALERT BRACELET TO PROTECT YOUR FISTULA FROM FAILURE AND SUPPORT
KIDNEYBUZZ.COM.
PURCHASE YOUR $5.00 "NO BLOOD PRESSURE (BP)/NO NEEDLE STICK (STICK)" MEDICAL ALERT BRACELET TO PROTECT YOUR FISTULA FROM FAILURE AND SUPPORT KIDNEYBUZZ.COM.
Note: Do not forget to order your No BP/No Stick Medical Alert Bracelet and your FREE KidneyBuzz.com Impact Meal Recipe Book!

Like Us on our Facebook Page for more Daily News and Information about life with CKD and ESRD:

https://www.Facebook.com/pages/KidneyBuzz/347471888696381?ref=hl
Source...
Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
You can unsubscribe at any time

Leave A Reply

Your email address will not be published.